Medicament for promoting hematopoietic function after radiotherapy

Abstract

The invention provides a medicament for promoting a hematopoietic function after radiotherapy. The medicament is prepared from the following medicaments: 20g of astragalus, 15g of pilose asiabell root, 15g of Chinese wolfberry, 10g of American ginseng, 15g of dwarf lilyturf tuber, 12g of Indian buead, 8g of Chinese magnoliavine fruit, 12g of largehead atractylodes rhizome, 12g of officinal magnolia bark, 7g of Chinese angelica, 8g of tangerine peel, 8g of tuber fleeceflower root, 8g of giant knotweed rhizome, 7g of eucommia bark, 8g of yerbadetajo herb, 8g of baked ginger and 4g of liquoric root. The medicament provided by the invention has a significant promotion effect on the hematopoietic function of cancer patients after radiotherapy.

Description

technical field [0001] The invention relates to a medicine with side effects after cancer radiotherapy, in particular to a medicine for promoting hematopoietic function after cancer radiotherapy prepared from Chinese herbal medicine. Background technique [0002] Radiation therapy is of great value in the comprehensive treatment of patients with malignant tumors, but some adverse reactions during radiotherapy cannot be ignored. It not only affects the quality of life and treatment effect of patients, but can even be life-threatening in severe cases. [0003] Bone marrow immature neutrophils and platelet precursors are rapidly dividing cells that are sensitive to radiotherapy. If the radiotherapy area contains a large amount of bone marrow, the patient is at risk for neutrophil and platelet counts, and radiotherapy should be delayed if neutrophil and platelet counts fall below safe levels. Infection and bleeding tendency caused by myelosuppression and hematopoietic dysfunct...

AI Technical Summary

Problems solved by technology

The occurrence of myelosuppression after radiotherapy is related to the type of malignant tumor, the constitution of the patient, the choice of irradiation field, and the dose of radiation. Therefore, it is still impossible to absolutely avoid the occurrence of low hematopoietic function after radiotherapy. Strengthen the treatment of patients with myelosuppression after radiotherapy It is very important to promote the hematopoietic function of bone marrow